Stay updated with breaking news from Aduhelm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biogen’s Alzheimer’s disease drug Aduhelm will only be covered for Medicare beneficiaries participating in a clinical trial. The final coverage determination will have the effect of limiting use of the drug, but the agency said its decision provides clarity on what drug companies need to show in order to secure Medicare coverage.
Medicare will only cover a drug for Alzheimer's disease for patients in clinical trials, President Joe Biden's administration ...
WASHINGTON (AP) — Medicare said Thursday it's considering a cut in enrollee premiums,...
Officials cited data showing the new Alzheimer’s drug has serious safety risks and may not help patients.
The Alzheimer’s Association has pushed relentlessly to get broad access to Aduhelm, despite safety risks and uncertain evidence that it helps patients.